Statement Of Cash Flows

Noile-Immune Biotech Inc. - Filing #7304911

Concept As at
2024-06-30
2024-01-01 to
2024-06-30
As at
2023-12-31
As at
2023-06-30
2023-01-01 to
2023-06-30
As at
2022-12-31
Statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-682,206,000 JPY
-832,341,000 JPY
Decrease (increase) in inventories
9,321,000 JPY
-4,243,000 JPY
Subtotal
-609,140,000 JPY
-506,784,000 JPY
Interest and dividends received
23,000 JPY
18,000 JPY
Income taxes paid
-2,420,000 JPY
-2,420,000 JPY
Cash flows from operating activities
Foreign exchange losses (gains)
JPY
382,000 JPY
Other, net
13,768,000 JPY
10,460,000 JPY
Net cash provided by (used in) operating activities
-611,479,000 JPY
-509,179,000 JPY
Cash flows from operating activities
Increase (decrease) in accounts payable - other
-1,430,000 JPY
24,605,000 JPY
Cash flows from investing activities
Net cash provided by (used in) investing activities
557,000 JPY
-5,316,000 JPY
Cash flows from facilities maintenance and investing activities
Cash flows from financing activities
Proceeds from issuance of shares
2,500,000 JPY
2,457,905,000 JPY
Net cash provided by (used in) financing activities
2,500,000 JPY
1,947,090,000 JPY
Net increase (decrease) in cash and cash equivalents
-608,422,000 JPY
1,432,595,000 JPY
Cash and cash equivalents
4,947,268,000 JPY
5,555,691,000 JPY
5,953,593,000 JPY
4,520,997,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.